N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated …

W Wick, S Dettmer, A Berberich, T Kessler… - Neuro …, 2019 - academic.oup.com
Background Patients with glioblastoma without O 6 -methylguanine-DNA methyltransferase (MGMT)
promoter hypermethylation are unlikely to benefit from alkylating chemotherapy with …

Long‐term safety and efficacy of Eculizumab in Aquaporin‐4 IgG‐positive NMOSD

…, R Diem, M Platten, A Berberich… - Annals of …, 2021 - Wiley Online Library
Objective During PREVENT (NCT01892345), eculizumab significantly reduced relapse risk
versus placebo in patients with aquaporin‐4 immunoglobulin G‐positive neuromyelitis …

Endovascular versus medical management of posterior cerebral artery occlusion stroke: the PLATO study

…, S Finitsis, MA Möhlenbruch, PA Ringleb, A Berberich… - Stroke, 2023 - Am Heart Assoc
BACKGROUND: The optimal management of patients with isolated posterior cerebral artery
occlusion is uncertain. We compared clinical outcomes for endovascular therapy (EVT) …

Endovascular therapy versus no endovascular therapy in patients receiving best medical management for acute isolated occlusion of the posterior cerebral artery: a …

A Berberich, S Finitsis, D Strambo… - European Journal of …, 2022 - Wiley Online Library
Background and purpose Endovascular therapy (EVT) is increasingly reported for treatment
of isolated posterior cerebral artery (PCA) occlusions although its clinical benefit remains …

Targeting resistance against the MDM2 inhibitor RG7388 in glioblastoma cells by the MEK inhibitor trametinib

A Berberich, T Kessler, CM Thomé, S Pusch… - Clinical Cancer …, 2019 - AACR
Purpose: Resistance is an obstacle of glioma therapy. Despite targeted interventions, tumors
harbor primary resistance or become resistant over short course of treatment. This study …

[HTML][HTML] Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

…, V Neff, R Diem, M Platten, A Berberich… - Multiple sclerosis and …, 2021 - Elsevier
Background Antibodies to the aquaporin-4 (AQP4) water channel in neuromyelitis optica
spectrum disorder (NMOSD) are reported to trigger the complement cascade, which is …

Leaving the day behind: endovascular therapy beyond 24 h in acute stroke of the anterior and posterior circulation

…, S Schönenberger, A Berberich… - Therapeutic …, 2022 - journals.sagepub.com
Background: There is little evidence of endovascular therapy (EVT) being performed in
acute ischemic stroke beyond 24 h, and that evidence is limited to anterior circulation stroke. …

Dual antiplatelet therapy improves functional outcome in patients with progressive lacunar strokes

A Berberich, C Schneider, T Reiff, C Gumbinger… - Stroke, 2019 - Am Heart Assoc
Background and Purpose— In 20% to 30% of patients with lacunar strokes, early neurological
deterioration (END) occurs within the first days after stroke onset. However, effective …

[HTML][HTML] Acute shortage of iodinated contrast media: implications and guidance for neurovascular imaging and intervention

DPO Kaiser, M Abdalkader, A Berberich, PB Sporns… - Neuroradiology, 2022 - Springer
In April 2022, the long-running lockdown in Shanghai, China, due to the COVID-19 pandemic
led to significant restrictions on the production of iodinated contrast media (ICM) of a major …

Diagnostic accuracy of automated occlusion detection in CT angiography using e-CTA

…, JAR Pfaff, Y Mokli, A Berberich… - … Journal of Stroke, 2022 - journals.sagepub.com
Background and aim The aim of this study was to assess the diagnostic accuracy of e-CTA (product
name) (Brainomix) in the automatic detection of large vessel occlusions in anterior …